Sökning: WFRF:(Kim Seong Min) > Cardiovascular even...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05431naa a2200685 4500 | |
001 | oai:DiVA.org:liu-181065 | |
003 | SwePub | |
008 | 211118s2022 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1810652 URI |
024 | 7 | a https://doi.org/10.1111/cts.131682 DOI |
040 | a (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Jung, Se Yongu Yonsei Univ, South Korea4 aut |
245 | 1 0 | a Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database |
264 | c 2021-10-31 | |
264 | 1 | b Wiley,c 2022 |
338 | a electronic2 rdacarrier | |
500 | a Funding Agencies|Yonsei University College of Medicine for 2021 [2021-32-0049] Funding Source: Medline | |
520 | a On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unknown. We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO). Disproportionality analyses of CV-ADRs associated with remdesivir were performed using reported odds ratios and information components. We conducted in vitro experiments using cardiomyocytes derived from human pluripotent stem cell cardiomyocytes (hPSC-CMs) to confirm cardiotoxicity of remdesivir. To distinguish drug-induced CV-ADRs from COVID-19 effects, we restricted analyses to patients with COVID-19 and found that, after adjusting for multiple confounders, cardiac arrest (adjusted odds ratio [aOR]: 1.88, 95% confidence interval [CI]: 1.08-3.29), bradycardia (aOR: 2.09, 95% CI: 1.24-3.53), and hypotension (aOR: 1.67, 95% CI: 1.03-2.73) were associated with remdesivir. In vitro data demonstrated that remdesivir reduced the cell viability of hPSC-CMs in time- and dose-dependent manners. Physicians should be aware of potential CV consequences following remdesivir use and implement adequate CV monitoring to maintain a tolerable safety margin. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Andra medicinska och farmaceutiska grundvetenskaper0 (SwePub)301992 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Other Basic Medicine0 (SwePub)301992 hsv//eng |
700 | 1 | a Kim, Min Seou Korea Univ, South Korea; Sungkyunkwan Univ, South Korea4 aut |
700 | 1 | a Li, Hanu Univ Florida, FL USA4 aut |
700 | 1 | a Lee, Keum Hwau Yonsei Univ, South Korea4 aut |
700 | 1 | a Koyanagi, Aiu Univ Barcelona, Spain; ICREA, Spain; Inst Salud Carlos III, Spain4 aut |
700 | 1 | a Solmi, Marcou Univ Ottawa, Canada; Ottawa Hosp, Canada; Univ Ottawa, Canada4 aut |
700 | 1 | a Kronbichler, Andreasu Med Univ Innsbruck, Austria4 aut |
700 | 1 | a Dragioti, Elenau Linköpings universitet,Avdelningen för prevention, rehabilitering och nära vård,Medicinska fakulteten,Region Östergötland, Smärt och rehabiliteringscentrum4 aut0 (Swepub:liu)eledr71 |
700 | 1 | a Tizaoui, Kalthoumu Tunis El Manar Univ, Tunisia4 aut |
700 | 1 | a Cargnin, Sarahu Univ Piemonte Orientale, Italy4 aut |
700 | 1 | a Terrazzino, Salvatoreu Univ Piemonte Orientale, Italy4 aut |
700 | 1 | a Hong, Sung Hwiu Yonsei Univ, South Korea4 aut |
700 | 1 | a Abou Ghayda, Ramyu Univ Hosp, OH USA; Case Western Reserve Univ, OH 44106 USA4 aut |
700 | 1 | a Kim, Nam Kyunu Emory Univ, GA 30322 USA; Yonsei Univ, South Korea4 aut |
700 | 1 | a Chung, Seo Kyoungu Ewha Womans Univ, South Korea4 aut |
700 | 1 | a Jacob, Louisu Univ Barcelona, Spain; Univ Versailles St Quentin En Yvelines, France4 aut |
700 | 1 | a Salem, Joe-Elieu Sorbonne Univ, France4 aut |
700 | 1 | a Yon, Dong Keonu Seoul Natl Univ, South Korea4 aut |
700 | 1 | a Lee, Seung Wonu Sejong Univ, South Korea4 aut |
700 | 1 | a Kostev, Karelu Univ Clin Marburg, Germany4 aut |
700 | 1 | a Kim, Ah Youngu Yonsei Univ, South Korea4 aut |
700 | 1 | a Jung, Jo Wonu Yonsei Univ, South Korea4 aut |
700 | 1 | a Choi, Jae Youngu Yonsei Univ, South Korea4 aut |
700 | 1 | a Shin, Jin Soou Korea Res Inst Chem Technol, Germany4 aut |
700 | 1 | a Park, Soon-Jungu T&R Biofab Co Ltd, Germany4 aut |
700 | 1 | a Choi, Seong Woou Seoul Natl Univ, South Korea4 aut |
700 | 1 | a Ban, Kiwonu City Univ Hong Kong, Peoples R China4 aut |
700 | 1 | a Moon, Sung-Hwanu T&R Biofab Co Ltd, Germany4 aut |
700 | 1 | a Go, Yun Youngu City Univ Hong Kong, Peoples R China4 aut |
700 | 1 | a Shin, Jae Ilu Yonsei Univ, South Korea4 aut |
700 | 1 | a Smith, Leeu Anglia Ruskin Univ, England4 aut |
710 | 2 | a Yonsei Univ, South Koreab Korea Univ, South Korea; Sungkyunkwan Univ, South Korea4 org |
773 | 0 | t Clinical and Translational Scienced : Wileyg 15:2, s. 501-513q 15:2<501-513x 1752-8054x 1752-8062 |
856 | 4 | u https://liu.diva-portal.org/smash/get/diva2:1612465/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.13168 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-181065 |
856 | 4 8 | u https://doi.org/10.1111/cts.13168 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy